The Industrial Technology Research Institute, a non-profit R& D organisation in Taiwan, has unveiled its AI-assisted system for detecting diabetic eye diseases.

WHAT IT’S ABOUT

Point-of-care AI-DR can instantly diagnose diabetic retinopathy and diabetic vision oedema inside five to 10 seconds. It can locate from fundus images four main lesions – microaneurysms, haemorrhages, soft exudates, and hard exudates – and detect two anatomical landmarks, the optic disc and the macular area. It can further identify 14 other common ocular fundus abnormalities, including retinal-related diseases, changes in blood vessels, and optic nerve-related illnesses.

AI-DR also provides five severity levels of diabetic retinopathy plus produces binary classifications for both diabetic retinopathy and diabetic macular oedema.

The particular AI model has been trained using 150, 000 fundus pictures. In a  study, AI-DR was shown to have 98% sensitivity and 96% specificity within diagnosing diabetic retinopathy.  

According in order to ITRI, AI-DR can support all available auswahl cameras worldwide and be used to create other solutions such as edge AI systems, standalone web applications, and private and public cloud-based services. The organisation has recently provided a use license with regard to AI-DR to Acer regarding its VeriSee DR diagnostic software.

WHY IT MATTERS

Last year, there are about 537 million adults between the age of 20 and 79 who have got diabetes. The International Diabetes Foundation expects their count to reach 643 million by 2030 plus 783 million by 2045.

Currently, more than half of people living with diabetes globally will develop DR and about one in 15 will build up DME, according to the US National Eye Institute.

ITRI said that with analysis solutions like AI-DR, the risks of blindness caused simply by diabetes complications can be lowered. It also emphasised that in diabetes management today, it is crucial to track changes in fundus symptoms because this could be better monitored than blood sugar levels.

Additionally , AI-DR’s intuitive design  allows GPs and other non-ophthalmologists to perform quick diabetic retinopathy screening as trained ophthalmologists, which  can lead  to increased screening rates, reduced treatment costs and improved patient outcomes by enabling early detection.

MARKET SNAPSHOT

Other existing  diabetic attention screening software program products  around Asia-Pacific are also powered simply by AI,   including  the  ORAiCLE   platform by New Zealand-based Toku Eyes,   Singapore Eye Lesion Analyzer   by the Singapore Eye Research Company, and  VUNO Med-Fundus AI   by South Korean medical AI company VUNO.

Meanwhile, a  recent Google-backed study in Thailand has demonstrated the accurate detection of diabetic retinopathy using a new  deep-learning system .  

Also, Samsung is  turning old Galaxy smartphone devices into AI-powered fundus cameras to screen for diabetic eye diseases as part of the upcycling programme to improve access to eyesight health testing in underserved communities around the world.

Leave a Reply

Your email address will not be published. Required fields are marked *